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Abstrak 
 
 
Objektif: 
 
Tujuan kajian ini adalah untuk mengenalpasti peratusan kejadian hypokalsemia sementara di 
kalangan pesakit yang menjalankan pembedahan kelenjar tiroid di Malaysia dan mengenalpasti 
sama ada pemberian ubat vitamin D kepada pesakit sebelum pembedahan dapat mengurangkan 
kejadian hypokalsemia. 
 
Tatacara: 
Kajian ini adalah kajian Randomized Control Trial yang melibatkan jumlah 74 orang pesakit dari 
Hospital Universiti Sains Malaysia dan Hospital Raja Perempuan Zainab II. Kajian ini bermula dari 5 
Mei 2008 sehingga 30 April 2010. Kajian ini telah mendapat kelulusan dari Jawatankuasa Etika ( 
Bahagian Manusia), Universiti Sains Malaysia dan Jawatankuasa Etika Institusi Penyelidikan Negara, 
Kementerian Kesihatan Malaysia. Tujuh puluh empat pesakit yang menjalani pembedahan kelenjar 
tiroid telah dipilih ke dalam dua kumpulan secara rambang.  Pesakit dari kumpulan kajian akan 
menerima ubat vitamin D ( calcitriol) 1.5ug sehari selama dua hari sebelum pembedahan diikuti oleh 
1.0ug sehari dan ubat kalsium laktat 1.8g sehari selama 7 hari sementara pesakit dari kumpulan 
kawalan tidak diberikan ubat vitamin D. Semua pesakit akan dinilai berdasarkan tanda-tanda  klinikal 
dan biokimia.  
 
 
xv 
 
Keputusan 
Tiada perbezaan yang ketara di antara kumpulan kajian dan kumpulan kawalan bagi faktor umur, 
jantina, penyakit, masa pembedahan, penanaman semula kelenjar paratirod, paras asal kalsium, 
fosfat dan paras hormon PTH. Kejadian hypokalsemia sementara  di kalangan kumpulan kajian 
adalah 16.7% berbanding dengan kajian kawalan adalah 75%. Dikalangan kes-kes ini, 50% daripada 
kumpulan kajian dan 64.3% daripada kumpulan kawalan adalah kes simptomatik. Kejadian kes 
hypoparatiroid kekal adalah 2.7%. Perbezaan yang ketara dikesan dalam kejadian hypokalsemia yang 
tidak simptomatik dan simptomatik di kalangan kumpulan  kajian dan kumpulan kawalan.  Perkara 
yang sama dikesan dalam kejadian perubahan aras kalsium mengikut masa di antara dua kumpulan 
ini. Tiada perbezaan yang ketara dalam kejadian hypoparatiroid kekal di kalangan dua kumpulan ini. 
Kumpulan kawalan menjalani tempoh rawatan hospital selepas pembedahan yang lebih panjang 
iaitu 4.59 hari berbanding dengan kumpulan kajian iaitu 3.92 hari. 
 
Kesimpulan 
Pemberian ubat vitamin D mempunyai kesan yang ketara untuk mengurangkan kejadian 
hypokalsemia sementara dalam kes pembedahan kelenjar tiroid. 
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Abstract 
 
 
Objective:  
The aim of our open label randomized control study was to determine the incidence of 
transient hypocalcemia developing post total thyroidectomy in Kelantan (Malaysia) and the 
benefit of pre-operative treatment using oral vitamin D for post total thyroidectomy. 
 
Methodology:  
This is a randomized control study which recruits a total of 74 patients from Hospital 
Universiti Sains Malaysia and Hospital Raja Perempuan Zainab II. The study was carried out 
over one year duration since 5th May 2009 until 30th April 2010. The ethical approval was 
obtained from The Research Ethical Committee (Human), Universiti Sains Malaysia and 
Ethical Board Clinical Research Center (CRC), Ministry of Health.  Seventy four patients 
that underwent total thyroidectomy were randomized into two groups. Study group: 37 
patients treated with oral vitamin D (calcitriol) 1.5ug/day for 2 days duration before operation 
followed by 1.0ug/day plus oral calcium lactate 1800mg/day for 7 days after operation. 
Control group: 37 patients did not receive oral Vitamin D or calcium lactate. All the patient 
were assessed  clinically and biochemically for hypocalcemia.  
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Result: 
There was no significant difference between the study and control group in terms of 
demographic distribution of age, sex, diagnosis, surgeon, operating duration, parathyroid 
gland autotransplant, and baseline level of serum calcium, phosphate and intact PTH. The 
incidence of post total thyroidectomy transient hypocalcemia in the study group is about 
16.7% compared with control group of 75%. Among the cases, 50.0% in the study group and 
64.3% in control group are symptomatic. The incidence of permanent hypoparathyroidism is 
2.7%. There was significant difference in term of incidence of asymptomatic hypocalcemia 
and symptomatic hypocalcemia between these two groups since p value is <0.001.  There 
was also significant difference between control and study group with regards to the trend of 
post-operative serum calcium changes since p value <0.001. However, there was no 
significant difference in the risk of developing permanent hypoparathyroidism.  The post 
operative stay is significantly longer in control group, 4.59 days compared with study group, 
3.92 days ( p value : 0.001). 
 
Conclusion: 
 The administration of oral vitamin D pre-operatively had significantly reduced the incidence 
of transient hypocalcemia post total thyroidectomy.  
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CHAPTER 1: INTRODUCTION 
 
Thyroid operation was introduced in year 1800s. During that time, the operation carries high 
risk and its mortality and morbidity was up to 40%. With the discovery and advancement in 
the knowledge of physiology and anatomy of thyroid gland, the improving surgical skills, 
techniques and new technology, the thyroid operation became a very safe operation. The 
general mortality and morbidity of this operation is now 0.5-1.0% (Sharma, 2007). 
 
The common complications of thyroid operation are bleeding, injury to the superior and 
recurrent laryngeal nerve, thyroid storm, hypothyroidism, transient hypocalcemia and 
infection (Burge 1998; Sharma 2007). Sterile techniques and standard operating theater 
procedure has reduced the rate of infection. The current infection rate is less than 1% 
(Dionigi, Rovera et al. 2008). Johnson and Wagner ( 1998) had conducted a retrospective 
study regarding use of prophylactic antibiotic in thyroid operation. They concluded thyroid 
operation is a clean operation and antibiotic is unnecessary. 
 
Thyroid gland is a very vascular gland. Previously, it was a very bloody operation. However, 
current surgical skill has grossly reduced the perioperative bleeding rate. Moreover, multiple 
trials and studies has been conducted to compare effectiveness of harmonic scarpel, ligasure, 
bipolar diathermy toward simple suture ligature method in terms of bleeding and surgery time 
(Cordón, Fajardo et al. 2005).  Schoretsanitis et al (1998) has conducted a randomized control 
study regarding the use of post-op drain in hemithyroidectomy and concluded that there is no 
difference between post-op with or without drain. There are also ongoing studies for post-op 
drain in total thyroidectomy. 
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Surgeon and patients alike are in constant fear of laryngeal nerve injury. A unilateral nerve 
injury causes hoarseness of the voice while complete bilateral nerve injury cause respiratory 
obstruction with loss of voice which may necessitates tracheostomy. Current knowledge of 
thyroid gland has improved the risk of laryngeal nerve injury to 0.2-1.0%. The risk for 
reoperation is relatively high and estimated about 2-12%. Recently, the use of  
Electromyography (EMG) to identify the recurrent laryngeal nerve in difficult cases is 
claimed to reduce the rate of nerve injury as well (Sharma, 2007). 
 
Hypoparathyroidism is another main thyroidectomy complication especially in the case of 
total thyroidectomy. The inferior parathyroid gland receives blood supply from inferior 
thyroid artery and superior parathyroid gland may receive blood supply from either superior 
or inferior thyroid artery. During mobilization of the thyroid gland, surgeon will indirectly 
injure or disturb the blood supply to the parathyroid gland. The parathyroid glands become 
ischemic and this will affect its function. If the ischemia is temporary then it only causes 
temporary hypoparathyroidism otherwise it can result in rarely occurring permanent 
hypoparathyroidism (Kihara, 2000; Sharma, 2007). 
 
The improvement in surgical technique has reduced the risk of parathyroid injury. Recently, 
many surgeons practice autotransplantation of parathyroid gland. However, preserving the 
original parathyroid gland is still the gold standard of thyroid operation. The technique of 
autotransplantation of parathyroid gland might help to reduce the risk of permanent 
hypoparathyroidism but it increases the risk of temporary hypoparathyroidism (Lo & Lam, 
1998). 
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The issue we are interested in is transient hypocalcemia. Despite advancement of surgical 
skill and new technique, rate of transient hypocalcemia did not change much. Currently, the 
risk of asymptomatic hypocalcemia is about 40-60% and symptomatic hypocalcemia is about 
15-25% (Sharma, 2007). This problem causes discomfort to the patient and might even 
threaten patient’s life and prolong hospital stay. There are many studies emphasizing on 
calcitriol and calcium supplement in post-op care given either during period of hypocalcemia 
or as a routine management (Tartaglia, Giuliani et al. 2005; Roh and Park, 2006). However, 
we are interested in the prevention of transient hypocalcemia rather than its treatment because 
prevention is definitely better than treating the complications. Testal et al had given oral 
vitamin D pre-operatively and achieve superior result in terms of preventing transient post 
total thyroidectomy hypocalcemia. However, oral calcium and hydrochlorothiazide were also 
given together with oral vitamin D in his study which causes side effects such as vomiting 
and giddiness due to hypercalcemia and hypotension.   His hypothesis is not based on using 
vitamin D to compensate for hypoparathyroidism instead to induce hypercalcemia before 
surgery ( Testa et al,2006). 
 
The pathogenesis of transient hypocalcemia is (1) impairment of blood supplies to 
parathyroid gland and causes the gland ischemic and affects its function. (2) the release of 
calcitonin from the parafollicular cell during removal of parathyroid gland. (3) ‘hunger bone 
syndrome’ secondary to sudden drop of high thyroid hormone after total thyroidectomy. 
Long period of hyperthyroidism causes bone hungry for calcium and sudden removal of the 
stimulus will cause bone aggressively absorb the calcium from the blood. It occurs in the case 
of pre-operative hyperthyroidism. Among these 3 hypotheses, parathyroid gland ischemia is 
the main factor for transient hypocalcemia (Sortino, Puccini et al. 1994; Sturniolo, Lo 
Schiavo et al. 2000; Sharma, 2007) 
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As we know calcium metabolism is based on 3 main hormones interaction: (1) parathyroid 
hormone, (2) calcitonin and (3)1,25-dihydrocholecalcitriol (vitamin D). Parathyroid hormone 
and vitamin D increases the blood calcium level meanwhile calcitonin reduces the blood 
calcium level. Parathyroid hormone inhibits bone osteoblastic activity and increase 
osteoclastic activity to release calcium from bone to the blood. It increases the vitamin D 
production and increase calcium absorption and phosphate secretion in the kidney. Vitamin D 
increases calcium absorption in the intestine and reduces calcium secretion in the kidney. It 
maintains the balance of bone metabolism. The calcitonin inhibits the osteoclastic activity in 
the bone (Linda S. Costanzo, 1998; mazzaferri, 2005; Moreno, 2006; Ganong, 1995). 
 
The question here is can vitamin D compensate for the sudden drop in parathyroid hormone 
to maintain the calcium level?  Parathyroid hormone has a very short half life about 2-3 
minutes (Linda S. Costanzo, 1998; Ganong, 1995). Most of the transient hypocalcemia is due 
to the temporary hypoparathyroidism which mostly recover within 1 week (Sturniolo, Lo 
Schiavo et al. 2000; Sianesi, Del Rio et al. 2006). Most of the thyroid operation is performed 
in an euthyroid patient. The issue of hunger bone syndrome may be uncommon. The 
hypothesis of calcitonin release during operation might be less important as calcitonin has a 
short half about 1 hour only (Wolfe HJ, 1975; Ganong, 1995). 
 
We have conducted a study in which we have given 0.5ug vitamin D 8 hourly to our patients 
for 2 days before he or she goes for total thyroidectomy operation followed by one week 
duration of 1.0ug vitamin D daily and 1800mg per day calcium lactate. Vitamin D has a half 
life of 8 hour and it takes about 5 half lives to achieve a stable vitamin D level (Kartzung, 
1995; Boger and Perrier, 2004; Glorieux, 2004). Our intention was to evaluate the effect of 
5 
 
vitamin D to compensate for the temporarily low parathyroid hormone by looking into the 
result of laboratory hypocalcemia and symptomatic hypocalcemia. A positive result from the 
study can then be incorporated into our clinical practice in total thyroidectomy management.  
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1.1 LITERATURE REVIEW OF POST TOTAL THYROIDECTOMY             
TRANSIENT  HYPOCALCEMIA                 
 
Thyroid operation has progressed tremendously since the past few decades. Currently, it is a 
safe operation and some centres have been performing this operation as a day care surgery 
with the general morbidity and mortality of 0.5-1.0%. However, the burdensome incidences 
of hypocalcemia is still taxing the surgeon despite many studies being conducted to look into 
this problem (Sharma, 2007). 
 
The incidence of transient hypocalcemia post total thyroidectomy case is 42% for 
asymptomatic hypocalcemia and 14 % for symptomatic hypocacemia (Gac, Cabane et al. 
2007). The independent risk factors for transient hypocalcemia are  female gender, elevated 
free thyroxine, total thyroidectomy and autotransplant parathyroid gland (Abboud, 2002). 
Grave’s disease and thyroid cancer has  relatively higher risk of post-op hypocalcemia 
(Tonioto, 2008). The incidence of transient hypocalcemia in autotransplanted parathyroid 
gland is higher (21.4%) compared to control group ( 8.1%) but the permanent hypocalcemia 
is lower in autotransplant group( 0%) compared to control group ( 26%) (Lo and Lam, 1998). 
 
Bellantone et al in 2002 had conducted a study to compare the incidence of transient 
hypocalcemia post total thyroidectomy among (1) control group (2) patient given oral 
calcium 3g per day after surgery and (3) patient given oral calcium 3g per day and vitamin D 
1ug per day after surgery. The findings shows group (3) had superior result with less 
incidence of hypocalcemia compared to group (1) and (2). No significant difference was 
noted between group (1) and group (2). Post operatively routine oral calcium did not  reduce 
the incidence of hypocalcemia.  (Rocco Bellantone, 2002).  
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A study was conducted by Roh and Park et al (2006) to compare routine administration of 
oral calcium 3g/d and calcitriol 1ug/d with control group prescribed with placebo in total 
thyroidectomy patient. The study group had lower laboratory hypocalcemia 13% versus 36% 
and lower symptomatic hypocalcemia 7% versus 24% (Roh and Park, 2006). 
 
F.Tartaglia et al (2005) had done a comparison between (1) patient given oral calcium 
1.5g/day only, (2) patient given oral calcium1.5g/d + oral vitamin D 1ug/day and (3) patient 
given oral calcium 1.5g/d + oral vitamin D 2ug/d. The result shows incidence of severe 
hypocalcemia ( tetany) in group (1) 7.4% , group (2) 2.9% and group (3) 0%. He concluded 
that Vitamin D 2ug/day in his study had significantly reduced the risk of severe 
hypocalcemia.  Risk of tetany is high if the serum calcium level is less than 7.5mg/dl. He 
noticed there was no difference of PTH recovery in these 3 groups after cessation of 
medication (Tartaglia, Giuliani et al. 2005).  He also concluded that oral calcitriol did not 
reduce the incidence of severe hypocalcemia at post-operative Day 1 but it had significant 
effect at post-operative Day 2. 
 
Sturniolo et al found that post total thyroidectomy hypocalcemia is a transient event with 
nadir of serum calcium level attained 24 hours after surgery and returned to normal level 
within seven days. A reduction in post-operative Day 1 PTH more than 75% show significant 
high risk of hypocalcemia  with positive predictive value of 100% (Sturniolo, Lo Schiavo et 
al. 2000). 
 
Oral calcitriol with oral calcium is the most recommended treatment to prevent post total 
thyroidectomy transient hypocalcemia after surgery (Rocco Bellantone 2002; Tartaglia, 
Giuliani et al. 2005; Roh and Park 2006). Recently, a study conducted in Italy by Testa et al 
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shows that pre-operative treatment with oral calcitriol had the additional benefit in reducing 
the incidence of transient hypocalcemia post total thyroidectomy. In this randomized control 
study, a group of patients prescribed with 1.5ug/day calcitriol plus hydrochlorothiazide for 1 
week before total thyroidectomy was compared with a group of patient given placebo. He 
noticed 1 out of 22 study patient (4.6%) developed asymptomatic hypocalcemia compared 
with 10 out of 20 patients (50%) in placebo group.  None of the study patient (0%) developed 
symptomatic hypocalcemia compared to 20% of the placebo group (Testa, Fant et al. 2006). 
 
Here, we conducted a study which is similar to the study done by Testa et al but we omitted 
using hydrochlorothiazide in view that this medication has the effect of lowering the blood 
pressure and sodium in the blood. No doubt this medication can reduce the incidence of 
hypercalciuria but it is more recommended for patients on long term treatment of oral 
calcitriol and calcium especially in the case of chronic renal failure. Hydrochlorothiazide can 
also cause hypercalcemia (Katzung, 1995). 
 
In our study, we had prescribed pre-operative treatment of oral calcitriol 0.5ug 8 hourly for 2 
days followed by another one week duration of oral calcitriol 1.0ug per day and oral calcium 
lactate 1.8g per day after the surgery. Our hypothesis is based on concept of utilizing vitamin 
D to compensate for the transient low PTH and most of the parathyroid gland function should 
recover in one week time. This study was conducted to assess the benefit of giving oral 
vitamin D to patient before he or she goes for total thyroidectomy.  We believe pre-operative 
treatment of oral vitamin D can give extra benefit compared to routine administration of 
vitamin D and calcium after surgery. Erbil et al had shown that low pre-operative vitamin D 
will increase risk up to 28 folds to develop hypocalcemia. Tartaglia et al claimed vitamin D 
did not reduce the risk of hypocalcemia on post operative day one due to its delayed effect. 
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However, Vitamin D significantly reduces the risk of hypocalcemia at post operative day two 
and day three.  The medication, Rolcalcitriol was chosen because it is an active form of 
vitamin D ( 1, 25-dihydroxyvitamin D) . This medication does not require to be activated 
either in the liver or kidney (ROCHE 2004). Thus, parathyroid hormone would not affect the 
vitamin D level because intact parathyroid hormone plays a major role in activation of 
vitamin D in the kidney.  Our intention was to utilize oral vitamin D to compensate for the 
transient hypoparathyroidism post total thyroidectomy. This medication was given for 2 days 
prior to surgery. The half lives of vitamin D was about 6- 8 hours (ROCHE, 2004). 
According to the principle of pharmacodynamic ,  five half lives are needed to achieve a 
plateau drug level (Kartzung, 1995). Oral rocalcitriol given with frequency three times a day 
for two days is considered adequate to achieve a plateau drug level.  The dosage of 1.5 ug 
oral rocalcitriol was chosen because this dosage is within the safe limit. The normal dosage 
for treating hypocalcemia in hypoparathyroidism patient ranges from 0.5- 2.0ug (Calcitriol, 
2010). 
 
Furthermore, most of the studies which used Vitamin D had demonstrated that it was safe to 
use vitamin D within the range of 1.0ug to 2.0ug. Testa et al used vitamin D 1.5 ug/day while 
Roh and Park et al and Bellantone et al used oral vitamin D 1.0ug /day. F. Targalia et al 
employed vitamin D 2.0ug/day and he claimed the effect of vitamin D 2.0ug/day is superior 
to the dosage of vitamin D 1.0ug/day. The medication is served three times per day based on 
its half lives of 6-8 hours. Dosage of 0.5 ug per dose is the dosage deemed as suitable for this 
study. 
 
Sinensi et al (2006) claimed most of the post total thyroidectomy patients achieves 
normocalcemia within one week (Sinensi et al, 2006). Sturniolo et al (2000) claimed low 
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calcium level in post total thyroidectomy patient lasted about 3 days and went back to normal 
level within 5 days (Sturniolo et al, 2000). All these studies indicate that transient 
hypoparathyroidism can recover in one week duration. Tartaglia et al (2005) claimed there  is 
no difference of parathyroid recovery if patient is treated with vitamin D, oral calcium or 
placebo (Tartaglia et al ,2005).   Loh and Park et al (2006) claimed administration of vitamin 
D does decrease the function of parathyroid hormone but did not prevent its recovery. In this 
study, oral vitamin D of one week duration with oral calcium supplement was utilised to 
compensate for the hypoparathyroidism while waiting for the parathyroid gland recovery 
(Loh and Park et al , 2006). 
 
Oral calcium lactate was chosen because it was more easily absorbed by the body.  It can be 
absorbed at various pH and does not need to be taken with food to facilitate absorption. 
Furthermore, it causes less gastric upset (Straub, 2007). However, the elemental calcium 
content in calcium lactate which constitute about 13% of its content is actually lower 
compared to other forms of calcium salts (Kartzung, 1995). In this dosage, it was given 
basically as supplement rather than treatment dose. A 600mg calcium tablet is given three 
times a day to meet the daily dosage of 1800mg and the total elemental calcium per day  of 
234mg. The daily requirement of calcium in adult is about 1000mg (Health, 1994). Hence, 
prevention of hypocalcemia mainly depends on vitamin D rather than on calcium lactate. 
Bellantone et al (2002) also claimed there was no significant difference in terms of 
hypocalcemia between post total thyroidectomy patient treated with either oral calcium  
3g/day or placebo (Bellantone et al, 2002). 
 
Serial serum calcium measurement was taken at 6 hours, 24 hours and 48 hours in this study. 
We believe most of the incidence of hypocalcemia will occur within 24 hour post operation. 
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Sturniolo et al (2000) found that post total thyroidectomy hypocalcemia is a transient event 
with nadir of serum calcium level being achieved 24 hours after surgery ( Sturniolo et al, 
2000). De Pasquale et al (2000) claimed 85% of hypocalcemia incidence occurs on post 
operative day one  ( De Pasquale et al ,2000). Nahas et al (2006) noted similar result (Nahas 
et al, 2006).  He found that if the serum calcium level is more than 2.00mmol/L at post 
operative 12 hours, it is unlikely for the patient to develop significant hypocalcemia. 
Considering previous findings by other researchers, we believe it is safe to discharge the 
patients if they had been normocalcemic at post operative 48 hours.  
 
The measurement of serum phosphate together with serum calcium is an extra objective in 
this study. As was widely known, serum phosphate level is highly correlated with serum 
iPTH and Vitamin D. Intact PTH function is to decrease serum phosphate meanwhile vitamin 
D is to increase serum phosphate. We were also interested to know the trend of serum 
phosphate after thyroidectomy. No study that was done before had actually looked into this 
aspect.  
 
In this study, we had intact parathyroid hormone ( iPTH) level measured after 24 hours post 
operatively. We believe it is easier to handle, cost effective and more accurate to predict 
hypocalcemia. Kara et al (2009) claimed a single measurement of iPTH taken any time from 
post operation 10 min will be able to predict post thyroidectomy hypocalcemia.  Toniato et al 
(2008) claimed iPTH measurement at post operative day one is less expensive than intra-
operative quick iPTH (Toniato et al, 2008).  In our setting,  iPTH quick test is more costly 
compared to conventional iPTH test.  Conventional iPTH measurement is also more reliable.  
Assessment of serum calcium, phosphate and intact PTH at post operative day fourteen were 
also undertaken to evaluate the recovery of parathyroid hormone. Participants both from the 
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control group and study group were compared to assess the effect of vitamin D toward the 
recovery process of parathyroid hormone.  
 
Vitamin D and oral calcium are safe medication which had been used for the treatment of 
hypocalcemia in the case of renal impairment, vitamin D deficiency and hypoparathyroidism 
(Roche 2004). Most of the recommended dose range from 0.5-2.0ug/d vitamin D. The daily 
requirement of calcium in normal adult is 800mg -1200mg (Drug.com-calcitriol). A high 
dose of vitamin D 38ug/d with Paclitaxel in treatment of  cancer did not show dose limiting 
toxicity (2002) Clinical pharmacotherapy ). The maximum dosage of calcium lactate that can 
be given is 9 g per day ( Food and Nutrition Board,Washington 1997). Thus, oral calcitriol 
1.5 ug/day and oral calcium lactate 1500mg/day are within a very safe dosage, furthermore it 
is given for a period of less than 10 days ( short duration). 
 
 Oral calcium supplement is well known to have multiple benefits to our health. It is not only 
used for the treatment of osteoporosis but it is believed  to have an effect in lowering the risk 
of hypertension, reducing cholesterol level and the risk of colorectal cancer (Allender PS, 
1996; Slattery M, 1999). However,  intravenous calcium might be able to  increase the risk of 
cardiac arrhythmias in patient taking digoxin and antagonise the effect of calcium channel 
blocker (Bar-Or D 1981).  Hence, these groups of patients were excluded from our study. 
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1.2 ANATOMY OF THYROID GLAND AND PARATHYROID GLAND 
 
 
1.2.1 Thyroid gland 
 
1.2.1.1 Embryology 
The thyroid medial precursor is derived from the ventral diverticulum of the endoderm from 
the first and second pharyngeal pouches at the foramen cecum (Hayes B 1985; Sessions 
1999). The diverticulum descends from the base of the tongue to its adult pretracheal position 
through a midline anterior path with the primitive heart and great vessels during weeks 4 to 7 
of gestation. The proximal portion of this structure retracts and degenerates into a solid, 
fibrous stalk; persistence of this tract can lead to the development of a thyroglossal duct cyst 
with variable amounts of associated thyroid tissue. The lateral thyroid primordia arise from 
the fourth and fifth pharyngeal pouches and descend to join the central component. 
Parafollicular C cells arise from the neural crest of the fourth pharyngeal pouch as 
ultimobranchial bodies and infiltrate the upper portion of the thyroid lobes (Copp DH, 1967). 
Because of the predictable fusion of the ultimobranchial bodies to the medial thyroid anlage, 
C cells are restricted to a zone deep within the middle to upper third of the lateral lobes 
(Wolfe HJ, 1975). 
1.2.1.2 Anatomy 
The thyroid gland is composed of two lateral lobes connected by a central isthmus, weighing 
15 to 25 g in adults. A thyroid lobe usually measures about 4 cm in height, 1.5 cm in width, 
and 2 cm in depth. The superior pole lies posterior to the sternothyroid muscle and lateral to 
the inferior constrictor muscle and the posterior thyroid lamina. The inferior pole can extend 
to the level of the sixth tracheal ring. Approximately 40% of patients have a pyramidal lobe 
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that arises from either lobes or the midline isthmus and extends superiorly (Hollingshead 
1958). 
The thyroid is enclosed between layers of the deep cervical fascia in the anterior neck. The 
true thyroid capsule is tightly adherent to the thyroid gland, and continues into the 
parenchyma to form fibrous septa separating the parenchyma into lobules. The surgical 
capsule is a thin, film like layer of tissue lying on the true thyroid capsule. Posteriorly, the 
middle layer of the deep cervical fascia condenses to form the posterior suspensory ligament, 
or Berry's ligament, connecting the lobes of the thyroid to the cricoid cartilage and the first 
two tracheal rings (Hollingshead W, 1958). 
Blood supply to and venous drainage of the thyroid gland involves two pairs of arteries, three 
pairs of veins, and a dense system of connecting vessels within the thyroid capsule. The 
inferior thyroid artery arises as a branch of the thyrocervical trunk. This vessel extends along 
the anterior scalene muscle, crossing beneath the long axis of the common carotid artery to 
enter the inferior portion of the thyroid lobe. Although variable in its relationship, the inferior 
thyroid artery lies anterior to the recurrent laryngeal nerve (RLN) in approximately 70% of 
patients.  The inferior thyroid artery is also the primary blood supply for the parathyroid 
glands (Hollingshead W ,1958). 
The superior thyroid artery is a branch of the external carotid artery and courses along the 
inferior constrictor muscle with the superior thyroid vein to supply the superior pole of the 
thyroid. This vessel lies posterolateral to the external branch of the superior laryngeal nerve 
(SLN) as the nerve courses through the fascia overlying the cricothyroid muscle. Care should 
be taken to ligate this vessel without damaging the SLN. Occasionally, arteria thyroidea ima 
may arise from the innominate artery, carotid artery, or aortic arch, and supply the thyroid 
gland near the midline.  Many veins within the thyroid capsule drain into the superior, 
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middle, and inferior thyroid veins, leading to the internal jugular or innominate veins. The 
middle thyroid vein travels without an arterial complement, and division of this vessel 
permits adequate rotation of the thyroid lobe to identify the recurrent laryngeal nerve (RLN) 
and parathyroid glands (Sinnatamby, 2006). 
The Recurrent Laryngeal Nerve provides motor supply to the larynx and some sensory 
function to the upper trachea and subglottic area. Careful management of thyroid carcinomas 
requires a thorough knowledge of the course of the RLN. During development, the RLN is 
dragged caudally by the lowest persisting aortic arches. On the right side, the nerve recurs 
around the fourth arch (subclavian artery), and on the left side, the nerve recurs around the 
sixth arch (ligamentum arteriosum) (Hollingshead, 1958; Sinnatamby, 2006) 
The right Recurrent Laryngeal Nerve leaves the vagus nerve at the base of the neck, loops 
around the right subclavian artery, and returns deep to the innominate artery back into the 
thyroid bed approximately 2 cm lateral to the trachea. The nerve enters the larynx between the 
arch of the cricoid cartilage and the inferior cornu of the thyroid cartilage. The left RLN 
leaves the vagus at the level of the aortic arch, and loops around the arch lateral to the 
obliterated ductus arteriosus. The nerve returns to the neck posterior to the carotid sheath and 
travels near the tracheoesophageal groove along a more medial course than the right RLN. 
The nerve crosses deep to the inferior thyroid artery approximately 70% of the time and often 
branches above the level of the inferior thyroid artery before entry into the larynx (Rosai, 
1992). 
 
The RLN travels underneath the inferior fibers of the inferior constrictor (i.e., the 
cricopharyngeus muscle) and behind the cricothyroid articulation to enter the larynx. A 
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“nonrecurrent” laryngeal nerve may rarely occur on the right side and enters from a more 
lateral course.  Ocasionally, an aberrant retroesophageal subclavian artery (arteria lusoria) or 
other congenital malformation of the vascular rings is present (Henry JF, 1988). 
The Superior Laryngeal Nerve arises beneath the nodose ganglion of the upper vagus and 
descends medial to the carotid sheath, dividing into an internal and external branch about 
2 cm above the superior pole of the thyroid. The internal branch travels medially and enters 
through the posterior thyrohyoid membrane to supply sensation to the supraglottis. The 
external branch extends medially along the inferior constrictor muscle to enter and supply  
the cricothyroid muscle.  Along its course, the nerve travels with the superior thyroid artery 
and vein. The nerve typically diverges from the superior thyroid vascular pedicle about 1 cm 
from the thyroid superior pole (Lennquist S, 1987). 
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1.2.2 Parathyroid gland 
 
 
1.2.2.1 Embryology 
 
The superior parathyroid gland arises from the fourth pharyngeal pouch. The inferior 
parathyroid gland developed from the third pouch but displaced caudally by the descent of 
the thymus from the same pouch (Sinnatamby, 2006).  
 
 
1.2.2.2 Anatomy 
 
The parathyroid glands are normally located behind the thyroid gland lobes. There are usually 
four glands in ninety percents of subjects, two glands on each side with each weighing about 
5g. The superior parathyroid gland is the most constant in position. It is usually within the 
thyroids pretracheal fascial capsule at the middle of the back of the thyroid lobe at the same 
level with the first tracheal ring and above the inferior thyroid artery. The inferior parathyroid 
gland is less constant in position. It is usually within the prethracheal fascial sheath behind 
the lower pole but it may be found inside the thyroid gland itself or outside the fascial sheath 
in variable position in the neck or in the superior or posterior mediastinum. They are 
brownish yellow in appearance. They are also easily subject to subcapsular haematoma 
formation on handling. Both glands is usually supplied by the inferior thyroid artery 
(Sinnatamby, 2006).  
 
1.2.2.3 Histology 
 
These glands consist of chief or principal cells which secrete the parathyroid hormone. It 
resembles lymphoid tissue but it can be differentiated from the former by the number of 
blood capillaries and oxyphil cells scattered among the chief cells (Sinnatamby, 2006). 
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1.3 Thyroid surgery and complication 
 
1.3.1 Thyroid surgery procedure 
The procedure is performed with patient lying in supine position.  A shoulder roll is used to 
hyperextend the neck. The neck is cleaned and draped. The neck is infiltrated with 20–30 ml 
of 1:100,000 epinephrine.  A skin crease collar incision is made about  2–3 cm or two finger-
breadths above the sternal notch. The incision is made with a number 10 blade with one 
sweep through the skin, subcutaneous tissue, platysma, and down to the avascular deep 
investing layer of fascia. Precaution are taken to avoid damage to the anterior jugular veins. 
Subplatysmal flaps are raised superiorly to the upper border of the thyroid cartilage and 
inferiorly to the sternal notch. The flaps are retracted using a self-retaining retractor. The 
sternohyoid muscle is separated along its median raphe and the plane underneath is disclosed 
using blunt dissection. If the thyroid is large, the straps muscle in the upper third is   divided 
to avoid damage to the ansa cervicalis. The thyroid gland is usually mobilized by initially 
dissecting the upper pole. The middle thyroid vein may have to be ligated to gain entry into 
the paracarotid tunnel.   Superior thyroid vessel is ligated close to the gland to avoid injuring 
the external branch of the superior laryngeal nerve.  Further dissection on the lateral and 
inferior parts of the thyroid gland is made to deliver the thyroid through the incision wound.  
 
With the surgeon standing on the same side as the lobe being removed, the assistant rolls the 
gland medially with a swab to expose the tracheo-oesphageal groove and thyroid bed (Hobbs, 
2007). The recurrent laryngeal nerve is always found in the Beahrs  triangle.  Surgeon has to 
be aware of non-recurrent nerve if recurrent laryngeal nerve is failed to be identified 
(Watkinson, 2007). The parathyroid glands are caramel-coloured and are often variable in 
size and position. The superior parathyroid can be found medial to the upper pole in Joll’s 
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triangle. The inferior parathyroid gland is more inconsistent in its position and mostly found 
on the lower part of thyroid gland below the inferior thyroid artery. Once  parathyroid glands 
have been identified, the inferior thyroid artery is ligated distal to the branches that supply the 
inferior parathyroid (G. Akerstrom, 1984).  The gland is fully mobilized by cutting through 
Berry’s ligament down onto the trachea. The pyramidal lobe and isthmus were dissected off 
the trachea. A similar procedure is performed at the contralateral lobe.  
 
After completely removing the thyroid, hemostasis should be secured before closing the skin 
(Hobbs, 2007).  The commonest site for bleeding is in the ‘triangle of concern’, consist of the 
trachea medially and the nerve laterally with the thyrothymic ligament and loose fat above 
the sternum at the base and Berry’s ligament at the apex. There are many small branches of 
the inferior thyroid artery within this triangle. After bleeding is secured, a drain is inserted. Its 
function is to reduce the seroma but not to substitute the hemostasis (C. Debry). The fascia 
overlying the strap muscles is closed in the midline using a 3-0 interrupted absorbable suture. 
The platysma and subcutaneous layer is reapproximated using the same suture after the 
shoulder roll is removed. Skin can be closed using either glue, stapler or non-absorbable 
suture (Hobbs, 2007). 
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1.3.2 Complication of thyroid surgery 
In the 1800s when thyroid surgery was first introduced, the mortality rate from thyroid 
surgery was approximately 40%. With the refinement of thyroid surgery, sterile surgical 
arenas and  general anesthesia , the complication of thyroid surgery was greatly reduced 
(Sharma, 2007). 
 
In general, complications of thyroid surgery can be divided into minor, rare, or major.  The 
minor complications are post operative seroma and poor scar formation.  A small seroma will 
reabsorbed naturally but large seroma might need aspiration under sterile method. A small 
skin incision at the skin crease and avoidance of excessive skin traction can minimise scar 
formation (Sharma, 2007). 
 
The major complications are bleeding, infection, injury to recurrent laryngeal nerve, injury to 
superior laryngeal nerve, hypoparathyroidism, hypothyroidism and thyroid storm. The 
incidence of post surgery bleeding is about 0.3-1.0% which can turn disastrous. A minor 
bleeding may cause hematoma while major bleeding can result in impending respiratory 
failure due to upper air obstruction. The immediate management is to re- open the incision 
site and drain out the hematoma at the bedside (Sharma 2007; Burge 1998).  The risk of 
infection is estimated at about 1-2%. The use of prophylactic antibiotic is unnecessary as 
thyroidectomy is generally considered as a clean surgery (Dionigi, Rovera et al. 2008).  
 
The most worrying complication feared by surgeons is injury to recurrent laryngeal nerve and 
superior laryngeal nerve.  An in depth knowledge of the anatomical variation of the nerves 
and meticulous surgical technique is imperative to reduce the risk of injury to these nerves 
(Chiang, Lee et al. 2004). The left recurrent laryngeal nerve branches from the vagus at the 
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level of the aortic arch. It then passes below the arch and reverses its course to continue 
superiorly, posterior to the aortic arch and into the visceral compartment of the neck. It 
travels near or in the tracheoesophageal groove until it enters the larynx just behind the 
cricothyroid articulation. The right recurrent laryngeal nerve branches from the vagus more 
superiorly than does the left, at the level of the subclavian artery. It loops behind the right 
subclavian artery and ascends superomedially toward the tracheoesophageal groove. It then 
continues superiorly until entering the larynx behind the cricothyroid articulation. The non-
recurrent laryngeal nerve is present in 0.5% of population with the right side being more 
common than the left side. The nonrecurrent laryngeal nerve branches from the vagus at 
approximately the level of the cricoid cartilage and directly enters the larynx without looping 
around the subclavian artery. A left-sided nonrecurrent laryngeal nerve Right Laryngeal 
Nerve can occur only when a right-sided aortic arch and ligamentum arteriosum are 
concurrent with a left retroesophageal subclavian artery.  
 
The land mark to identify the recurrent laryngeal nerve is at the inferior thyroid artery. If the 
surgeon fails to identify the nerve then he must take precaution at the Berry ligament area 
about 0.5cm below the inferior thyroid corn of thyroid cartilage as it is the entry point to the 
larynx. The recurrent laryngeal nerve is always found at the tubercle of Zuckerkandl 
(Hollingshead 1958; Hayes B 1985; Henry JF 1988; Paul G. Gauger and Reeve 2001; 
Ferwins 2003). Monitoring the Recurrent Laryngeal Nerve during thyroid surgery using 
electrophysiology device is not done routinely  in thyroidectomy yet because there is no 
randomized study to compare the rate of postoperative Recurrent Laryngeal Nerve palsy in 
visual versus electrophysiologic Recurrent Laryngeal Nerve detection in thyroid surgery 
(Ferwins, 2003; Sharma, 2007). 
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There are two options of surgical treatment for laryngeal nerve injury either medialization or 
reinnervation. In medialization,  a window in the thyroid cartilage is created at the level of the 
true vocal fold. An implant is then placed to push the vocal fold medially. Medialization also 
can be done with an injection of absorbable teflon sponge  (Ferwins 2003; Sharma 2007).  A 
number of reinnervation procedures have been described for addressing the permanently 
injured Recurrent Laryngeal Nerve. These procedures maintain or restore the intrinsic 
laryngeal musculature tone. Primary neurorrhaphy may be used to immediately repair the 
transected Recurrent Laryngeal Nerve. Reinnervation procedures have been described by 
using the phrenic nerve, ansa cervicalis, and preganglionic sympathetic neurons. 
Improvement in phonation after reinnervation with the ansa cervicalis was found, but no 
movement is observed. Transfer of neuromuscular pedicles technique have been recently 
described and reportedly restore movement of the vocal fold (Ferwins, 2003; Sharma, 2007). 
 
Another complication was post thyroidectomy hypoparathyroidism.  The rate of transient 
hypoparathyroidism reported as 2-53% and permanent hypoparathyroidism was 0.4-13.8%. 
The cause of transient hypocalcemia after surgery is not clearly understood (Kihara 2000; 
Sharma 2007). It might be due to reversible parathyroid gland ischemia, parathyroid gland 
hypothermia, calcitonin release or hungry bone syndrome.  Hungry-bone syndrome occurs in 
patients with preoperative hyperthyroidism. These patients have increased bone breakdown in 
their hyperthyroid state. When a patient's thyroid hormone level drops acutely after surgery, 
his or her stimulus to break down bone is removed. The bones, now "hungry" for calcium, 
remove calcium from the plasma and decreasing serum calcium level (Sortino, Puccini et al. 
1994; Sturniolo, Lo Schiavo et al. 2000; Sharma 2007). 
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It is very dangerous to perform thyroidectomy in the hyperthyroid patient. The patient is not 
only at high risk for hypoparathyroidism but can also result in thyroid storm. Signs of 
thyrotoxic storm in the anesthetized patient include evidence of increased sympathetic output, 
such as tachycardia and hyperthermia. Other symptoms and signs in the fully awake patient 
include nausea, tremor, altered mental status or cardiac arrhythmias. Urgent medical 
treatment is needed. Intravenous beta-blockers, PTU, sodium iodine, and steroids are 
administered to control sympathetic activity, the release of thyroid hormone, and 
hyperthermia. Use cooling blankets and cooled intravenous fluids to reduce the patient's body 
temperature and monitor the oxygenation because oxygen demands increases during a thyroid 
storm (Ferwins 2003; Sharma 2007). 
 
Superior laryngeal nerve injury should not be neglected. The rate of injury to this nerve is 
quite high in thyroidectomy with estimate about 3-25%.  The effect of superior laryngeal 
nerve injury is inability to produce high pitch sound. Caution should be made to prevent this 
nerve injury by learning its anatomy. This nerve travels across the superior thyroid artery 
more than 1 cm above the upper pole of the thyroid gland (42%), less than 1 cm above the 
upper pole (30%), or under the upper pole (14%).  Ligation of the terminal branches of the 
superior thyroid artery is made as close to the thyroid capsule as possible to avoid damaging 
the nerve. The treatment for superior laryngeal nerve is speech therapy (Paul G. Gauger and 
Reeve 2001,Ferwins 2003). 
 
Lastly, all patients who have undergone thyroidectomy required lifelong thyroid hormone 
replacement. Thyroid function test also need to be monitored every 4-6 weeks until 
appropriate dosage are achieved (Sharma, 2007.) 
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1.4 Calcium and calcium metabolism 
  
1.4.1 Calcium 
 
Calcium has two important physiologic functions. The first function is to provide the 
structural foundation on which bones are built to protect internal organs, weight bearing 
function, and as levers for the muscles to act during movement. Second, soluble calcium ions 
in the extracellular fluid (ECF) and cytosol are important for an innumerable biochemical 
reactions, signaling cascades, and electrical systems that are necessary for life.  
An adult human contains about 1000 g of calcium, the majority (99%) of which is found in 
bone.  Approximately 1% of total body calcium is contained within the ECF and soft tissues. 
Therefore, the skeletal bone is utilized as a source of calcium when the ECF concentration 
falls and at the same time act as a storehouse for excess calcium. The ionized fraction is 
generally estimated to be approximately 50% of the total circulating calcium, with the 
remainder of the total serum calcium (40%) bound to serum proteins, primarily albumin. 
Another 10% of the total serum calcium are complexed with anions, such as citrate or sulfate. 
The ionized fraction of total serum calcium is physiologically important (biologically active) 
and is regulated tightly. Although it is possible to measure ionized calcium routinely in large 
clinical laboratories, proper handling of the specimen is imperative for it to be obtained 
anaerobically and analyzed promptly. Therefore, total serum calcium is often used as an 
indirect assessment of the ionized calcium fraction (Wysolmerski, 2007). 
Plasma protein concentration, plasma anion concentration and acid-base abnormalities may 
play an important role in influencing the proportion of ionic calcium and non-ionic calcium. 
An increase in the plasma protein will increase the total calcium concentration while 
decreases are associated with decrease in total calcium concentration. However, the changes 
in plasma protein concentration usually develop slowly over time and do not cause a parallel 
